Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28496485 | 0.81 | CYP3A4 (0.63) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL28904708 | 0.81 | CYP3A4 (0.63) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL26782451 | 0.79 | CYP3A4 (1.00) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL1043816 | 0.77 | CYP3A4 (0.75) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL10607082 | 0.77 | CYP3A4 (0.75) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL10607336 | 0.77 | CYP3A4 (0.75) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL6667574 | 0.77 | CYP3A4 (0.75) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL10608362 | 0.77 | CYP3A4 (0.75) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL10607245 | 0.77 | CYP3A4 (0.66) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A | |
| SCHEMBL28501713 | 0.77 | CYP3A4 (0.61) | CYP3A4ALDH1A1ALKBH5SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62084078-A | — | — | None | — | — | JP | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| WO-2014012054-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20100280061-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BARBIER LINDSAY BURNS | 2010-11-04 | — | — | US | disclosed |
| US-20100280061-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BARBIER LINDSAY BURNS | 2010-11-04 | — | — | US | disclosed |
| WO-2010051374-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-0219371-B1 | ANISOLE DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1989-11-08 | — | — | EP | disclosed |
| US-4746747-A | Anisole derivatives | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1988-05-24 | — | — | US | disclosed |
| EP-0219371-A2 | Anisole derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1987-04-22 | — | — | EP | disclosed |
| JP-S6284078-A | PRODUCTION OF N-PHENETHYLFORMAMIDE COMPOUND | MITSUBISHI CHEM IND LTD | 1987-04-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | CYP3A4 4048/4885ALDH1A1 3552/4885ALKBH5 2518/4885 |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | CYP3A4 4699/4885ALDH1A1 4388/4885ALKBH5 3944/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | CYP3A4 4699/4885ALDH1A1 4388/4885ALKBH5 3944/4885 |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | CYP3A4 4699/4885ALDH1A1 4388/4885ALKBH5 3944/4885 |
| US-20100280061-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | FLNA, FLNB, OPRL1 | CYP3A4 3247/4885ALDH1A1 1235/4885ALKBH5 2999/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | CYP3A4 4699/4885ALDH1A1 4388/4885ALKBH5 3944/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | CYP3A4 4699/4885ALDH1A1 4388/4885ALKBH5 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.